{"id":"NCT03232073","sponsor":"Actelion","briefTitle":"Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis","officialTitle":"Multicenter, Non-comparative Extension of Study AC-058B301, to Investigate the Long-term Safety, Tolerability, and Control of Disease of Ponesimod 20 mg in Subjects With Relapsing Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-07-05","primaryCompletion":"2024-01-16","completion":"2024-01-16","firstPosted":"2017-07-27","resultsPosted":"2025-02-21","lastUpdate":"2025-06-22"},"enrollment":877,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Ponesimod","otherNames":[]}],"arms":[{"label":"Ponesimod","type":"EXPERIMENTAL"}],"summary":"The study AC-058B301 (OPTIMUM; NCT02425644) has been designed to investigate the efficacy, safety and tolerability of ponesimod in subjects with relapsing multiple sclerosis (RMS). The AC-058B303 study is the long-term extension for the core study AC-058B301. The purpose of this long term extension of the core study AC-058B301 is to characterize the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with RMS.","primaryOutcome":{"measure":"Annualized Confirmed Relapse Rate (ARR)","timeFrame":"From randomization in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months","effectByArm":[{"arm":"Ponesimod 20 mg (Core and Extension Study)","deltaMin":0.143,"sd":null},{"arm":"Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension)","deltaMin":0.184,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":148,"countries":["United States","Belarus","Bosnia and Herzegovina","Bulgaria","Canada","Croatia","Czechia","Finland","France","Georgia","Germany","Greece","Hungary","Israel","Italy","Latvia","Lithuania","Mexico","Poland","Portugal","Romania","Russia","Serbia","Spain","Sweden","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":56,"n":439},"commonTop":["Covid-19","Alanine Aminotransferase Increased","Nasopharyngitis","Lymphopenia","Headache"]}}